company background image
IVX logo

Invion ASX:IVX Stock Report

Last Price

AU$0.005

Market Cap

AU$32.1m

7D

0%

1Y

-28.6%

Updated

25 Feb, 2024

Data

Company Financials

IVX Stock Overview

Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of various cancers, atherosclerosis, and infectious diseases in Australia.

IVX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Invion Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Invion
Historical stock prices
Current Share PriceAU$0.005
52 Week HighAU$0.008
52 Week LowAU$0.004
Beta1.16
1 Month Change0%
3 Month Change-28.57%
1 Year Change-28.57%
3 Year Change-50.00%
5 Year Change-64.29%
Change since IPO-98.73%

Recent News & Updates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Invion Limited's (ASX:IVX) CEO For Now

Nov 22
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Invion Limited's (ASX:IVX) CEO For Now

We Think Invion (ASX:IVX) Can Afford To Drive Business Growth

Jul 07
We Think Invion (ASX:IVX) Can Afford To Drive Business Growth

Recent updates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Invion Limited's (ASX:IVX) CEO For Now

Nov 22
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Invion Limited's (ASX:IVX) CEO For Now

We Think Invion (ASX:IVX) Can Afford To Drive Business Growth

Jul 07
We Think Invion (ASX:IVX) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Invion's (ASX:IVX) Cash Burn Situation

Mar 24
Here's Why We're Not Too Worried About Invion's (ASX:IVX) Cash Burn Situation

Is Invion (ASX:IVX) In A Good Position To Invest In Growth?

Dec 08
Is Invion (ASX:IVX) In A Good Position To Invest In Growth?

We're Not Very Worried About Invion's (ASX:IVX) Cash Burn Rate

Aug 16
We're Not Very Worried About Invion's (ASX:IVX) Cash Burn Rate

A Look At The Fair Value Of Invion Limited (ASX:IVX)

Nov 04
A Look At The Fair Value Of Invion Limited (ASX:IVX)

Estimating The Intrinsic Value Of Invion Limited (ASX:IVX)

Mar 23
Estimating The Intrinsic Value Of Invion Limited (ASX:IVX)

We Think Invion (ASX:IVX) Can Easily Afford To Drive Business Growth

Nov 26
We Think Invion (ASX:IVX) Can Easily Afford To Drive Business Growth

Shareholder Returns

IVXAU PharmaceuticalsAU Market
7D0%2.7%-0.02%
1Y-28.6%60.9%4.7%

Return vs Industry: IVX underperformed the Australian Pharmaceuticals industry which returned 60.6% over the past year.

Return vs Market: IVX underperformed the Australian Market which returned 4.7% over the past year.

Price Volatility

Is IVX's price volatile compared to industry and market?
IVX volatility
IVX Average Weekly Movement29.3%
Pharmaceuticals Industry Average Movement11.4%
Market Average Movement8.6%
10% most volatile stocks in AU Market16.9%
10% least volatile stocks in AU Market3.3%

Stable Share Price: IVX's share price has been volatile over the past 3 months.

Volatility Over Time: IVX's weekly volatility (29%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2000n/aThian Chewhttps://www.inviongroup.com

Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of various cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, anogenital, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion’s IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer.

Invion Limited Fundamentals Summary

How do Invion's earnings and revenue compare to its market cap?
IVX fundamental statistics
Market capAU$32.12m
Earnings (TTM)-AU$1.61m
Revenue (TTM)AU$4.10m

7.8x

P/S Ratio

-19.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IVX income statement (TTM)
RevenueAU$4.10m
Cost of RevenueAU$2.90m
Gross ProfitAU$1.21m
Other ExpensesAU$2.82m
Earnings-AU$1.61m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.00025
Gross Margin29.39%
Net Profit Margin-39.34%
Debt/Equity Ratio0%

How did IVX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.